Black-Ops, your posts have been very spot on and obviously tempered with wisdom and experience.
Just focusing on the HIV treatment here. COVID is a completely different topic and would be awesome if that gets released for treatment ASAP.
Since current HIV patients (health care covered) need maintenance drugs to the tune of $15-25K/year, wouldn't a good price point be in the range of $300-$500/dose (one dose per week per year = $15,600 - $26,000) to make it comparable in price but vastly superior in benefit? Not sure of production and delivery costs, but amortizing the costs over a few years to near term debt service and incrementally reward shareholders make sense, IMHO.
Do you now if the FDA application for HIV included exclusivity? I know CytoDyn has requested 7-year exclusivity in GvHD in March 2020, but not aware of a request for HIV treatment.